• BIOMAP is a consortium led by Laboratories Rovy  that includes Vivacell Biotechnology Spain, Vaxdyn,  and Bionaturis
  • The Feder-Interconecta Programme, via the Centre for the Development of Industrial Technology (CDTI, in Spanish), has granted Bionaturis 572.988€ for this biomedicine development initiative.

Jerez de la Frontera, January 12nd 2016. Bionaturis Group will take part in the BIOMAP consortium, devoted to the multivariate design of assays, with the ultimate goal of developing biomedicines using the pharmaceutical criteria for quality, security and efficacy designs (Quality by design or QbD).

The QbD method will be applied to the candidate selection processes for the development portfolio of each company in the consortium, reducing time and optimizing the process. In addition, these innovations aim to position the companies both technologically and commercially by providing the market with the scale-up system for structurally complex and highly-powerful biologics that will be both time and cost competitive.

The BIOMAP consortium is led by Laboratories Rovi and includes Vaxdyn, Vivacell Biotechnology Spain, and Bionaturis. In particular, Bionaturis will receive an incentive of 572.988€ granted by the CDTI from the Feder-Interconecta Programme, with the support of the Ministry of Economy and Competitiveness.

About Bionaturis

Bionaturis Group offers cutting-edge biotechnological drugs and services for human and animal health. Considered an international benchmark in vaccines research, the biotechnological Group which envisions a global access to health is listed on the Spanish stock exchange for SMEs (ticker BNT).

www.bionaturis.com

TO DOWNLOAD THE PRESS RELEASE, PLEASE, CLICK HERE

 

For further information:

Bionaturis Press

Virginia Montero

+34 856 818 424 / 655 311047

press@bionaturis.com

 

Disclaimer

The Market and investors are informed that the Company’s new developments are subject to significant risks and uncertainties, that include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Bionaturis’ ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Bionaturis’ patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

 Currently, there are no guarantees that the development product will receive the necessary regulatory approvals or that they will prove to be commercially successful.